Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

14.28 +0.43 (+3.10%)
Streaming Delayed Price Updated: 1:27 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Why Arcturus Therapeutics Stock Is Skyrocketing Today ↗
Investors are applauding Arcturus' collaboration with CSL. 
Via The Motley Fool
News headline image
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? ↗
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology. 
Via InvestorPlace
News headline image
Where Arcturus Therapeutics Stands With Analysts ↗
Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines ↗
 
Via Benzinga
News headline image
BARDA Backs Arcturus' Influenza Vaccine Program ↗
 
Via Benzinga
News headline image
Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Arcturus Therapeutics ↗
Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
News headline image
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket ↗
Gainers Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! 
Via InvestorPlace
News headline image
4 Analysts Have This to Say About Arcturus Therapeutics ↗
  Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: 
Via Benzinga
News headline image
Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Recap: Arcturus Therapeutics Q2 Earnings ↗
  Arcturus Therapeutics (NASDAQ:ARCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Arcturus Therapeutics to Attend the Following Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
7 Small-Cap Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later ↗
With the market taking a dip and possibly poised to incur more red ink, these are the small-cap stocks to buy that appeal to contrarians. 
Via InvestorPlace
News headline image
Arcturus Therapeutics to Attend the Following Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗
  
Via Benzinga
News headline image
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics ↗
Over the past 3 months, 6 analysts have published their opinion on Arcturus Therapeutics (NASDAQ:ARCT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
93 Biggest Movers From Yesterday ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
News headline image
70 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.